NOXXON's core focus is on discovering and developing Spiegelmers* using its platform technology for use in oncology. Its lead candidate, NOX-A12, is under development as a combination therapy for a number of cancer indications where its impact on the tumor microenvironment is intended to significantly enhance the effectiveness of anti-cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy without adding significant new side effects for patients.

In addition, NOXXON's Spiegelmer platform technology has generated clinically-validated assets which represent partnering opportunities. These include NOX-E36 for diabetic nephropathy.

Pipline NOXXON